KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $1.91.

  • Alnylam Pharmaceuticals' EPS (Basic) rose 31954.02% to $1.91 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.31, marking a year-over-year increase of 11187.74%. This contributed to the annual value of -$2.18 for FY2024, which is 3817.59% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' EPS (Basic) stood at $1.91, which was up 31954.02% from -$0.51 recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' EPS (Basic) ranged from a high of $1.91 in Q3 2025 and a low of -$3.32 during Q3 2022
  • Its 5-year average for EPS (Basic) is -$1.12, with a median of -$1.4 in 2023.
  • Data for Alnylam Pharmaceuticals' EPS (Basic) shows a peak YoY increase of 31954.02% (in 2025) and a maximum YoY decrease of 29230.77% (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' EPS (Basic) stood at -$2.18 in 2021, then increased by 23.01% to -$1.68 in 2022, then surged by 34.3% to -$1.1 in 2023, then surged by 40.55% to -$0.66 in 2024, then soared by 391.08% to $1.91 in 2025.
  • Its EPS (Basic) was $1.91 in Q3 2025, compared to -$0.51 in Q2 2025 and -$0.44 in Q1 2025.